Stay updated with breaking news from Precision Phenotypes. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Neumora Expands Precision Neuroscience Pipeline with Novel M4 Receptor Modulator Program Through Exclusive License Agreement with Vanderbilt University - read this article along with other careers information, tips and advice on BioSpace
Neumora Therapeutics has formally launched with $500 million and the goal of bringing to market precision therapies targeting neuropsychiatric disorders and neurodegenerative diseases stemming from disorders of the brain.
/PRNewswire/ -- Amgen (NASDAQ: AMGN) and Neumora Therapeutics, Inc. (Neumora), a clinical-stage biopharmaceutical company pioneering precision medicines for...
Press release content from PR Newswire. The AP news staff was not involved in its creation.